6:02 PM
 | 
Dec 18, 2013
 |  BC Extra  |  Top Story

Gilead reports data for sofosbuvir/NS5A combo

Next quarter, Gilead Sciences Inc. (NASDAQ:GILD) plans to submit an NDA to FDA and an MAA to EMA for an oral, once-daily, fixed-dose combination of the company's Sovaldi sofosbuvir ( GS-7977) and ledipasvir ( GS-5885) to treat chronic HCV genotype 1 infection. Gilead disclosed the plans after reporting data on Wednesday for three Phase III trials evaluating the fixed-dose combo,...

Read the full 296 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >